Brokerage Firm Rating Update on Momenta Pharmaceuticals (MNTA)

Momenta Pharmaceuticals (MNTA) : Zacks Investment Research ranks Momenta Pharmaceuticals (MNTA) as 3, which is a Hold recommendation. 4 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 3 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 7 research analysts is 1.86, which indicates as a Buy.

Momenta Pharmaceuticals (MNTA) has been rated by 6 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $20 and the lowest price target forecast is $13. The average forecast of all the analysts is $15.67 and the expected standard deviation is $3.08.


For the current week, the company shares have a recommendation consensus of Buy. Also, JP Morgan maintains its rating on Momenta Pharmaceuticals (NASDAQ:MNTA). The global brokerage major lowers the current price target from $21 per share to $15 per share. Analysts at the JP Morgan have a current rating of Overweight on the shares. The rating by the firm was issued on August 5, 2016.

Momenta Pharmaceuticals (NASDAQ:MNTA): stock was range-bound between the intraday low of $11.19 and the intraday high of $12.23 after having opened at $11.37 on Wednesdays session. The stock finally closed in the red at $11.37, a loss of -3.27%. The stock remained in the red for the whole trading day. The total traded volume was 997,557 shares. The stock failed to cross $12.23 in Wednesdays trading. The stocks closing price on Thursday was $12.23.

Momenta Pharmaceuticals, Inc. (Momenta) is a biotechnology company focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has three product areas: Complex Generics, Biosimilars and Novel Therapeutics. The Companys product, a generic version of Lovenox (enoxaparin sodium injection), was approved by the United States Food and Drug Administration. The Company is developing Complex Generics, such as Enoxaparin Sodium Injection and M356. The Company is developing Bosimilars, including M923 and M834. The Company is developing Novel Therapeutics, including Necuparanib. The Company is developing M356 as a generic version of Copaxone. The Company is developing M923, a biosimilar of HUMIRA. The Company is developing M834 as a biosimilar of ORENCIA.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.